Iterion Therapeutics announced that two abstracts featuring its first-in-class TBL1 inhibitor, tegavivint, will be presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting.
Morning Overview on MSN
Researchers find some cancer drugs work differently than their stated targets
As of spring 2026, a cancer drug that has spent years in clinical development as a Wnt/beta-catenin pathway blocker has been ...
Cancer stem cells (CSCs), a critical subpopulation within tumors, drive cancer initiation, progression, metastasis, relapse, ...
Cancer stem cells (CSCs), a critical subpopulation within tumors, drive cancer initiation, progression, metastasis, relapse, ...
Cancer stem cells (CSCs), a critical subpopulation within tumors, drive cancer initiation, progression, metastasis, relapse, and resistance to therapy ...
Seoul National University College of Engineering (SNU Engineering) announced that a joint research team led by Prof. Sunghoon ...
Researchers at Baylor College of Medicine have uncovered a previously unrecognized mechanism by which inherited calcium ...
A new study shows inherited calcium channel mutations disrupt brain development before birth, increasing epilepsy risk and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results